Skip to main content

Table 1 Patient characteristics

From: Metabolic imaging with FDG-PET and time to progression in patients discontinuing immune-checkpoint inhibition for metastatic melanoma

Characteristic Reason for discontinuation Overall
(n = 38)
Durable response (n = 27) Toxicity
(n = 11)
Age
 Median (range) 58 (38 – 81) 52 (33—86) 58 (33—86)
Sex
 female 13 (48.1%) 3 (27.3%) 16 (42.1%)
 male 14 (51.9%) 8 (72.7%) 22 (57.9%)
AJCC
 IIIB 4 (14.8%) 1 (9.1%) 5 (13.2%)
 IV M1a 1 (3.7%) 3 (27.3%) 4 (10.5%)
 IV M1b 4 (14.8%) 2 (18.2%) 6 (15.8%)
 IV M1c 14 (51.9%) 5 (45.5%) 19 (50.0%)
 IV M1d 4 (14.8%) 0 (0%) 4 (10.5%)
BRAF status
 Mutated 10 (37.0%) 5 (45.5%) 15 (39.5%)
 Wildtype 17 (63.0%) 5 (45.5%) 22 (57.9%)
 Not reported 0 (0%) 1 (9.1%) 1 (2.6%)
Regimen
 Ipilimumab/Nivolumab 16 (59.3%) 8 (72.7%) 24 (63.2%)
 Nivolumab 4 (14.8%) 1 (9.1%) 5 (13.2%)
 Pembrolizumab 7 (25.9%) 2 (18.2%) 9 (23.7%)
Duration of immunotherapy
 Median (range) 24 (8.7 – 48) 1.3 (0.69—22) 19 (0.69—48)
Prior surgery 22 (81.5%) 9 (81.8%) 31 (81.6%)
Prior radiotherapy 8 (29.6%) 2 (18.2%) 10 (26.3%)
Prior systemic therapy
 IFN 8 (29.6%) 1 (9.1%) 9 (23.7%)
 Immunotherapy 7 (25.9%) 0 (0%) 7 (25.9%)
 Targeted therapy 4 (14.8%) 3 (27.3%) 7 (18.4%)
 Chemotherapy 2 (7.4%) 0 (0%) 2 (5.3%)
 Other 2 (7.4%) 1 (9.1%) 3 (7.9%)
Toxicity ≥ grade 3 12 (44.4%) 11 (100%) 23 (60.5%)
LDH elevateda 3 (11.1%) 2 (18.2%) 5 (13.2%)
S100 elevateda 0 (0%) 3 (27.3%) 3 (7.9%)
RECIST v1.1 groupa
 CR 11 (40.7%) 2 (18.2%) 13 (34.2%)
 PR 14 (51.9%) 7 (63.6%) 21 (55.3%)
 SD 2 (7.4%) 2 (18.2%) 4 (10.5%)
  1. aat time of discontinuation
  2. Abbreviations: AJCC American Joint Classification of Cancer